Q32 Bio Inc. is a clinical-stage biotechnology company developing biologic therapeutics that target potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its primary focus is on bempikibart (ADX-914), a fully human anti-IL-7Rα antibody designed to block signaling mediated by IL-7 and TSLP, thereby re-regulating adaptive immune function. This candidate is being evaluated in the ongoing Phase 2 SIGNAL-AA trial for alopecia areata, with enrollment completed in Part B and topline data anticipated in mid-2026. Previously, the company advanced ADX-097, a tissue-targeted complement inhibitor, through Phase 1 and into Phase 2 development for complement disorders before selling it to Akebia Therapeutics while retaining its underlying platform, including ADX-096 for potential ophthalmologic indications. Q32 Bio also maintains other C3d mAb fusions and nanobodies aimed at tissue-targeted complement inhibition. Headquartered in Waltham, Massachusetts and founded in 2017, Q32 Bio plays a role in the biotechnology sector by addressing unmet needs in immune-mediated conditions through innovative antibody-based therapies.